» Articles » PMID: 17699418

Cumulative Excretion of Urinary Podocytes Reflects Disease Progression in IgA Nephropathy and Schönlein-Henoch Purpura Nephritis

Overview
Specialty Nephrology
Date 2007 Aug 21
PMID 17699418
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have revealed that podocytopenia leads to glomerular scarring and that the loss of podocytes into the urine may be a cause of podocytopenia. The purpose of this study was to examine whether serial examinations of urinary podocytes (u-podo) could be a useful predictor of disease progression in children with glomerulonephritis. Urine samples and renal biopsy specimens from 20 patients (10 males and 10 females; mean age 11.8 yr; range 4 to 24 yr) with IgA nephropathy (n = 17) and Henoch-Schönlein purpura nephritis (n = 3) were analyzed. Forty-four renal biopsies were performed on 20 patients. Proteinuria (g/d per 1.73 m2), hematuria (score), and u-podo (cells/ml) were examined twice a month in 24 intervals between two biopsies (mean 16.7 mo; range 4 to 58 mo) and average and cumulative values were determined for the intervals. Renal histologic changes were scored on the basis of acute intracapillary, acute extracapillary, acute tubulointerstitial, chronic intracapillary, chronic extracapillary, and chronic tubulointerstitial lesions, as well as glomerulosclerosis. It was found that hematuria, proteinuria, u-podo, and acute lesion scores decreased during the intervals examined, whereas chronic lesion scores increased. Changes in acute histology scores correlated well with hematuria, proteinuria, and u-podo excretion, whereas chronic histology scores and glomerulosclerosis both correlated well with cumulative u-podo excretion. Patients with severe histologic progression of disease also had persistent u-podo excretion. These findings provide additional data to support a potential causative role for prolonged urinary loss of podocytes in disease progression in children with IgA nephropathy and Henoch-Schönlein purpura nephritis.

Citing Articles

Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy.

Chen X, Wang M, Yan Z Diabetol Metab Syndr. 2025; 17(1):84.

PMID: 40051002 PMC: 11887226. DOI: 10.1186/s13098-025-01655-2.


Contemporary review of IgA nephropathy.

Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.

PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.


Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases.

Fukuda A, Sato Y, Shibata H, Fujimoto S, Wiggins R Clin Exp Nephrol. 2024; 28(6):496-504.

PMID: 38402504 PMC: 11116200. DOI: 10.1007/s10157-024-02465-y.


Evaluating the State of Glomerular Disease by Analyzing Urinary Sediments: mRNA Levels and Immunofluorescence Staining for Various Markers.

Yamamoto K, Oda T, Uchida T, Takechi H, Oshima N, Kumagai H Int J Mol Sci. 2024; 25(2).

PMID: 38255818 PMC: 10815027. DOI: 10.3390/ijms25020744.


Early growth response 1 as a podocyte injury marker in human glomerular diseases.

Okabe M, Koike K, Yamamoto I, Tsuboi N, Matsusaka T, Yokoo T Clin Kidney J. 2024; 17(1):sfad289.

PMID: 38186896 PMC: 10768762. DOI: 10.1093/ckj/sfad289.